CA2116138A1 - Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients - Google Patents

Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients

Info

Publication number
CA2116138A1
CA2116138A1 CA002116138A CA2116138A CA2116138A1 CA 2116138 A1 CA2116138 A1 CA 2116138A1 CA 002116138 A CA002116138 A CA 002116138A CA 2116138 A CA2116138 A CA 2116138A CA 2116138 A1 CA2116138 A1 CA 2116138A1
Authority
CA
Canada
Prior art keywords
xenograft rejection
compositions
methods
recipient
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002116138A
Other languages
French (fr)
Other versions
CA2116138C (en
Inventor
Heather A. Good
David K. C. Cooper
Andrew J. Malcolm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alberta Research Council
Integris Baptist Medical Center Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1992/007071 external-priority patent/WO1993003735A1/en
Publication of CA2116138A1 publication Critical patent/CA2116138A1/en
Application granted granted Critical
Publication of CA2116138C publication Critical patent/CA2116138C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Antibody-mediated xenograft rejection is attenuated by (i) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's cieculation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.
CA002116138A 1991-08-23 1992-08-21 Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients Expired - Fee Related CA2116138C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74952991A 1991-08-23 1991-08-23
US07/749,529 1991-08-23
PCT/US1992/007071 WO1993003735A1 (en) 1991-08-23 1992-08-21 Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients

Publications (2)

Publication Number Publication Date
CA2116138A1 true CA2116138A1 (en) 1993-03-04
CA2116138C CA2116138C (en) 2006-04-04

Family

ID=36143210

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002116138A Expired - Fee Related CA2116138C (en) 1991-08-23 1992-08-21 Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients

Country Status (1)

Country Link
CA (1) CA2116138C (en)

Also Published As

Publication number Publication date
CA2116138C (en) 2006-04-04

Similar Documents

Publication Publication Date Title
EP0661980A4 (en) Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients.
AU679437B2 (en) Induced tolerance to xenografts
HK1102293A1 (en) Graft rejection suppressors
Greenstein et al. The use of tolerance for transplantation across xenogeneic barriers
EP1003552A4 (en) LO-CD2a ANTIBODY AND USES THEREOF FOR INHIBITING T CELL ACTIVATION AND PROLIFERATION
EP0700297A4 (en) Surrogate tolerogenesis for the development of tolerance to xenografts
AU1716297A (en) Patient-specific immunoadsorbers for the extracorporeal apheresis and methods for their preparation
Teranishi et al. Depletion of anti-gal antibodies in baboons by intravenous therapy with bovine serum albumin conjugated to gal oligosaccharides
SOARES et al. IN VIVO DEPLETION OF XENOREACTIVE NATURAL ANTIBODIES WITH AN ANTI-μ MONOCLONAL ANTIBODY1, 2
Rydberg et al. Studies on the removal of anti‐pig xenoantibodies in the human by plasmapheresis/immunoadsorption
CA2116138A1 (en) Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients
Shaw et al. Pancytopenia responding to treatment of hyperthyroidism: a clinical case and review of the literature
CA2157500A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
WO2004052305A3 (en) Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
Ross et al. Parathyroid transplantation: fate of a long-term allograft in man
Starzl et al. Clinical xenotransplantation
HK1021318A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
US20020168371A1 (en) Process for reducing antibody response against xenografts
Guttmann et al. RENAL TRANSPLANTATION IN THE INBRED RAT: XII. A Mechanism of Long-Term Survival of Allografts After Antithymocyte Immunoglobulin Treatment: 1, 2
US5736136A (en) Immunoglobulin infusion in xenotransplantation
Kanai et al. Delayed hyperacute xenograft rejection in porcine to canine fetal liver transplantation
Friend Rejection reactions to different organ transplants
Bustos et al. The pathology of cardiac xenografts
Nikaein et al. Correlation of HLA-class II genotyping with MLC and unrelated bone marrow transplant outcome
Sridhar et al. Flowcytometric crossmatching in renal transplantation: Experience with quadruple immunosuppression

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed